Given its complex and context-dependent nature, GSDMB exemplifies a “double-edged sword.” On one hand, it can exert tumor-suppressive effects, as demonstrated in gastric and lung cancers, where GSDMB synergizes with immune checkpoint inhibitors and cisplatin to enhance anti-tumor responses. This evidence concerns the gene GSDMB and lung cancer.